Physician profile
Christopher I Shaffrey
NPI 1235208877
$4,535,572.74
in general payments reported to CMS, 2019-2025
22 companies · $1.2M in 2025
The $1.2M reported for 2025 was more than what 99% of Neurological Surgery providers received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $893K · 2020: $657K · 2021: $397K · 2022: $369K · 2023: $466K · 2024: $557K · 2025: $1.2M.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $1.8M · Consulting Fee: $298K · Travel and Lodging: $54K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $35K · Food and Beverage: $18K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $1,815,593.88 |
| Consulting Fee | $297,766.67 |
| Travel and Lodging | $53,576.91 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $34,960.75 |
| Food and Beverage | $18,245.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nuvasive, INC. | $1,648,962.65 | 2019-2023 | Versatie, Tlx, Archon |
| Si-Bone, INC. | $899,655.74 | 2019-2025 | |
| Medtronic, INC. | $823,636.46 | 2021-2025 | Cd Horizon Spinal System, Unid_pass, Verte-Stack Spinal System |
| Zimmer Biomet Holdings, INC. | $381,215.00 | 2019-2022 | |
| Medtronic USA, INC. | $318,732.57 | 2019-2020 | |
| Globus Medical, INC. | $280,255.77 | 2019-2025 | Tlx, Base, Versatie |
| Alphatec Spine, INC | $92,585.74 | 2019-2025 | Other - Miscellaneous, Osseoscrew |
| Zimvie INC. | $38,951.00 | 2022-2023 | |
| Siemens Medical Solutions USA, INC. | $19,229.99 | 2019 | |
| Mml US, INC. | $17,885.85 | 2021-2025 | Reactiv8 |
| Depuy Synthes Products, INC. | $10,262.40 | 2019 | |
| Medical Device Business Services, INC. | $2,308.03 | 2020-2025 | Conduit, Velys |
| Carlsmed, INC. | $418.36 | 2021-2024 | Aprevo |
| Cerapedics INC. | $308.78 | 2023-2024 | I-Factor Peptide Enhanced Bone Graft |
| Depuy Synthes Sales INC. | $259.59 | 2019-2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spinal Elements, INC. | $240.94 | 2022 | |
| Stryker Corporation | $239.68 | 2020-2022 | |
| Curiteva, INC. | $146.81 | 2024 | |
| Exactech, INC. | $105.92 | 2024 | |
| Orthofix Medical, INC. | $59.48 | 2025 | 7d Surgical System, Miscellaneous |
| Highridge Medical LLC | $55.99 | 2025 | Spine-None |
| Ebi, LLC | $55.99 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$4,726,443.78 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Shaffrey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.